As more and more pharmaceuticals enter the market in lyophilized form, reconstitution at the point of use is becoming increasingly prevalent. The MixJect system is one of West’s safe administration products that streamline this process. The delivery system allows for needleless reconstitution prior to injection and is equipped with a 21-gauge needle that can be covered by a shield both before and after the drug is administered, making administration of TRELSTAR® and disposal of the used syringe and vials significantly easier and safer for patients and caregivers alike.
“Convenience and safety are of the utmost importance for the patients and healthcare providers using West’s products; our reconstitution systems address both of these issues simultaneously,” said Graham Reynolds, Vice President, Safety and Administrations Systems, West. “The MixJect system is an excellent delivery system for Trelstar® and an example of our continued commitment to developing innovative products that meet the needs of pharmaceutical and biopharmaceutical customers and the patient populations they serve. Our partnership with Watson is proof that leading drug manufacturers continue to view West as a trusted resource for drug administration options.”
About West
West is the world’s premier manufacturer of components and systems for improving the safety and effectiveness of therapeutic and diagnostic health care delivery systems. This includes ready-to-sterilize and ready-to-use stoppers and seals for vials, plungers and other prefillable syringe components and an assortment of safety, reconstitution and delivery system capabilities and services. The Company also provides products with application to the personal care, food and beverage markets. West’s customers include the world’s leading pharmaceutical, biotechnology, generic drug and medical device producers. Headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at westpharma.com.
About TRELSTAR®
TRELSTAR®, developed by Debiopharm Group, a Swiss biopharmaceutical development specialist, and marketed by Watson Pharmaceuticals, Inc., is a synthetic hormone known as a luteinizing hormone releasing hormone (LHRH) agonist, which suppresses the production of testosterone in the testicles. The growth of the prostate is regulated in part by the level and activity of testosterone. TRELSTAR® is available in a 4-week depot formulation (TRELSTAR® DEPOT) and a 12-week long-acting formulation (TRELSTAR® LA), offering an alternative treatment for advanced prostate cancer when orchiectomy (removal of the testicles) or estrogen administration are either not indicated or unacceptable to the patient. TRELSTAR® does not require refrigeration and should be stored at controlled room temperature.
In clinical trials, the most common adverse events occurring in patients were hot flushes, skeletal pain, impotence and headache. As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels and may initiate or worsen symptoms during this transient period. Rare post-marketing reports of anaphylactic shock and angioedema have been reported. TRELSTAR® is contraindicated for use in women who are or may become pregnant. For additional information, please discuss with your physician or contact Watson Medical Communications at 866-75-J3315.
